Legal Representation
Attorney
Frank Terranella
USPTO Deadlines
Next Deadline
227 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2020-02-25)
Due Date
February 25, 2026
Grace Period Ends
August 25, 2026
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
32 eventsDate | Code | Type | Description |
---|---|---|---|
Feb 25, 2025 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
Nov 4, 2023 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
Nov 26, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED |
Jul 17, 2020 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
Jun 25, 2020 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
Jun 25, 2020 | FIMP | P | FINAL DISPOSITION PROCESSED |
May 25, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
Feb 25, 2020 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
Dec 10, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
Dec 10, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
Nov 20, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Nov 3, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
Nov 3, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
Nov 3, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
Nov 3, 2019 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
Nov 3, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
Sep 17, 2019 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
Sep 17, 2019 | GNFR | O | FINAL REFUSAL E-MAILED |
Sep 17, 2019 | CNFR | R | FINAL REFUSAL WRITTEN |
Aug 14, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Aug 14, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Aug 14, 2019 | ALIE | A | ASSIGNED TO LIE |
Aug 5, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Jun 8, 2019 | RFNT | P | REFUSAL PROCESSED BY IB |
May 22, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
May 22, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU |
Apr 30, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
Apr 26, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
Apr 25, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
Apr 24, 2019 | DOCK | D | ASSIGNED TO EXAMINER |
Apr 24, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Apr 18, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 001
Chemical, biochemical and biotechnological products, namely, chemical, biochemical and biotechnological agents used for non-medical purposes, namely, agents for quantifying and analyzing peptides, enzymes, hormones and metabolites involved in the renin-angiotensin-aldosterone system; chemical preparations, namely, chemical preparations for quantifying and analyzing peptides, enzymes, hormones and metabolites involved in the renin-angiotensin-aldosterone system; biochemical agents, namely, biochemical agents for quantifying and analyzing peptides, enzymes, hormones and metabolites involved in the renin-angiotensin-aldosterone system; buffers, namely, buffers for quantifying and analyzing peptides, enzymes, hormones and metabolites involved in the renin-angiotensin-aldosterone system
Class 005
Diagnostic agents for pharmaceutical purposes containing chemical preparations, biochemical agents, buffers, and diagnostic reagents, also in the form of kits, for medical purposes in the field of treating diseases related to the renin-angiotensin-aldosterone system, including cardiovascular disorders, in particular hypertension and primary aldosteronism
Class 009
Downloadable computer software, application software, mobile application software, software development tools in the nature of computer software, database software in the nature of computer software for use in database management, all aforementioned goods downloadable and related to the medical field, namely, for researching diagnosing, preventing, combating, treating and monitoring the treatment of diseases related to the renin-angiotensin-aldosterone system, including cardiovascular disorders, in particular hypertension and primary aldosteronism
Class 042
Medical and scientific research and analysis services in the nature of quality measurement and analysis for medical practices, and software design and development concerning quantifying and analyzing peptides, enzymes, hormones and metabolites involved in the renin-angiotensin-aldosterone system in the field of researching, diagnosing, preventing, combating, treating, and monitoring the treatment of diseases related to the renin-angiotensin-aldosterone system, including cardiovascular disorders, in particular hypertension and primary aldosteronism
Class 044
Medical services, medical care, medical testing in the nature of medical diagnostic testing; providing information in the field of medical information, namely, in the fields of diagnosing, preventing, combating, treating and monitoring the treatment of diseases related to the renin-angiotensin-aldosterone system, including cardiovascular disorders, in particular hypertension and primary aldosteronism
Additional Information
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
001
005
009
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"RAAS"
USPTO Documents
Loading USPTO documents...